title: [Clinical analysis of 1,000 patients with prostate cancer].
abstract: OBJECTIVE
  Treatment outcomes for prostate cancer in our hospital were reported.
  
  
  METHODS
  We analyzed 1,009 patients with prostate cancer treated at Niigata Cancer Hospital between 1983 and 2003.
  
  
  RESULTS
  As for the clinical stage, 20 cases belonged to Stage I, 367 cases to Stage II, 269 cases to Stage III and 353 cases to Stage IV. The overall 5-year survival rate of the all 1,009 cases was 59.0%, comprising 78.2% for stage I, 82.0% for Stage II, 76.0% for Stage III and 30.0% for Stage IV cases. Disease-specific 5-year survival rates for Stage I, II, III and IV were 100%, 96.8%, 89.3% and 41.1% respectively. In Stage III patients, the radiotherapy (with endocrine therapy) group showed longer cause-specific survival than the endocrine therapy group (p = 0.0056).
  
  
  CONCLUSIONS
  Our result suggest that the radiotherapy with endocrine therapy is useful for Stage III prostate cancer.
authors.affiliation: Department of Urology, Niigata Cancer Center Hospital, Niigata, Japan.
authors.forename: Toshihiro
authors.initials: T
authors.lastname: Saito
authors.forename: Takashi
authors.initials: T
authors.lastname: Kasahara
authors.forename: Yasuo
authors.initials: Y
authors.lastname: Kitamura
authors.forename: Shuichi
authors.initials: S
authors.lastname: Komatsubara
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D003131:Combined Modality Therapy; D006801:Humans; D007564:Japan / Q000453:epidemiology; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000401:mortality* / Q000473:pathology* / Q000532:radiotherapy; D012189:Retrospective Studies; D015996:Survival Rate
chemical_list: D018931:Antineoplastic Agents, Hormonal